https://www.selleckchem.com/products/plx8394.html
18% (5.59-17.82%, I - 92%), 10.22% (6.01-16.85%, I - 79%), and 0.72% (0.34-1.51, I - 0%) respectively. The prevalence of outcome 2 in subgroup analysis for HCQ and HCQ+Azithromycin was 7.25% (3.22-15.52, I - 59%) and 8.61% (4.52-15.79, I - 76%), respectively. The risk ratio (RR) for outcome 1 and outcome 2 between HCQ+Azithromycin and HCQ was 1.22 (0.77-1.93, I - 0%) 1.51 (0.79-2.87, I - 13%), respectively and was not significant. Heterogeneity was noted statistically as well clinically (regimen types, patient numbers, study desig
Like
Comment
Share
